Insider At Medical Device Maker Buys More Than 7,500 Shares
Transaction value based on SEC Form 4 weighted average purchase price ($19.74); post-transaction value based on Sept. 3, 2026 market close ($19.40).
Key questions
- How does the acquisition price compare to current market levels?
Oliver Engert executed the purchase at a weighted average price of $19.74 per , while the stock was priced at $18.56 as of the Sept. 4, 2026 market close. - What is the scale of the insider’s total equity position ing this move?
The addition of 7,598 s brings the total direct holding to 61,238 s, representing an ownership stake of 0.11% in the $1.1 billion medical technology enterprise. - What pricing ranges were reported for this acquisition?
According to regulatory footnotes, the s were acquired in multiple transactions at price ranges of $19.33 to $19.75 and $20.145 to $20.50, respectively. - What are the current financial fundamentals reported by the company?
Enovis Corporation reported trailing twelve-month revenue of $2.3 billion and a net loss of $1.1 billion as of the most recent reporting period.
Company Overview
| Metric | Value |
|---|---|
| Price (as of market close 2026-09-04) | $18.56 |
| Market Capitalization | $1.1 billion |
| Revenue (TTM) | $2.3 billion |
| Net Income (TTM) | -$1.1 billion |
Company Snapshot
- Enovis Corporation designs, manufactures, and distributes specialized medical devices for the treatment of musculoskeletal conditions, serving orthopedic specialists, surgeons, pain management experts, physical therapists, and other healthcare professionals across global markets.
- The company generates revenue through the sale of innovative medical device solutions that address degenerative illnesses, deformities, and traumatic injuries, leveraging a diversified product portfolio across orthopedic and musculoskeletal care segments.
- Enovis serves a broad customer base, including orthopedic surgeons, general physicians, pain management specialists, physical therapists, podiatrists, chiropractors, and athletic trainers who treat patients requiring musculoskeletal interventions and rehabilitation solutions.
Enovis Corporation is a global medical technology enterprise with approximately 7,802 employees and TTM revenues of $2.3 billion, positioning it as a significant player in the medical devices sector focused on musculoskeletal health solutions. The company operates across multiple therapeutic areas and geographic markets, serving healthcare professionals who treat patients with complex orthopedic and musculoskeletal conditions. Despite current profitability challenges reflected in TTM net losses, Enovis maintains a substantial revenue base and market presence in the specialized medical device industry.
What this transaction means for investors
Not all insider transactions have the same impact. Some are executed for tax purposes; others are done for estate planning. However, insider buys send a more clear message. They signal that an insider believes the company’s stock is undervalued and is willing to put their own money on the line. Nonetheless, retail investors shouldn’t blindly buy simply because insiders are. Instead, investors should review a company’s fundamentals. With that in mind, let’s have a look at Enovis (ENOV).
First off, let’s take a look at how ENOV stock has performed. Since 2021, the company’s s have generated a total return of -76%, equating to a compound annual growth rate (CAGR) of -24.9%. The S&P 500, meanwhile, has delivered an 83% total return, with a 12.9% CAGR over the same period.
Expand
NYSE: ENOV
Enovis
Today’s Change
(-4.05%) $-0.78
Current Price
$18.50
Key Data Points
Market Cap
$1.1BMarket cap calculated using publicly traded s outstanding only. Does not include unlisted, private, or dual-class non-traded s. Implied market cap may vary.
Day’s Range
$18.50 – $19.69
52wk Range
$18.08 – $34.28
Volume
277.6K
Avg Vol
1.3M
Gross Margin
53.34%
Turning to its core fundamentals, ENOV paints a mixed picture. On the one hand, free cash flow has increased significantly in recent years. After hitting a multi-year low of $(150) million in 2023, free cash flow has risen to $64 million now. In addition, revenue has climbed to $2.3 billion, up from $1.5 billion in 2022.
However, concerns remain. Profitability is a big one. ENOV continues to record net losses. The company’s net loss over the last 12 months stands at $(1.1) billion. Moreover, net debt stands at $1.36 billion, presenting a significant hurdle for the stock.
All in all, the recent insider buys provide confidence that management sees brighter days ahead. In addition, the company’s improving free cash flow lends credibility to this thesis. However, several key metrics, such as net debt and ongoing net losses, indicate that ENOV still faces challenges.
Read Next
•By Sara Appino
AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
•By Eric Volkman
•By Sara Appino
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
•By Keith Speights
Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock.
Novo Nordisk May Be Poised to Outpace Eli Lilly With This Key Catalyst
•By Thomas Niel
Should You Buy Bristol Myers Squibb Stock Right Now for the Yield Alone?
About the Author
Jake Lerch is a contributing Motley Fool technology analyst covering artificial intelligence, cloud computing, cybersecurity, e-commerce, and semiconductors. Prior to The Motley Fool, Jake worked for 12 years at Credit Suisse, an international investment bank. He holds a bachelor’s degree in business with a concentration in economics from the University of North Carolina at Wilmington.
Stocks Mentioned
Enovis
NYSE: ENOV
$18.50
(-4.05%)-$0.78
Motley Fool Stock Advisor’s Latest Pick
—% Avg Return
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Sumber Artikel:
Fool.com